Drug Trial Radar · NCT07503639
Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer
Last checked: Nov 20, 2026Latest source record: Mar 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
134
Planned (sponsor's estimate)
Start
Apr 2026
Primary completion
Apr 2028
Study completion Apr 2030
Sponsor
- Lead sponsor
- Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 31, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, open-label, single-center, phase II umbrella trial designed to evaluate the efficacy and safety of neoadjuvant therapy for locally advanced colorectal cancer. Patients will be stratified into four cohorts based on microsatellite instability (MSI) status, KRAS mutation status, and the consensus molecular subtypes (CMS). Six arms are included across four cohorts and each arm will be assigned to a specific treatment regimen. The primary endpoint is the complete response rate. Secondary endpoints include safety, organ preservation rate (for rectal cancer only), R0 resection rate, surgical complications, treatment compliance, 3-year survival, and quality of life (QoL) score.
Conditions
- Locally Advanced Colorectal Cancer
Interventions
SHR-1701Drug
1800mg d1 q3w
SHR-8068Drug
280mg,C1D1
Short-course radiotherapyRadiation
25Gy/5Fx
XELOX (Capecitabine and Oxaliplatin)Drug
Oxaliplatin: 130mg/m2 d1 q3w Capecitabine: 1000mg/m2 bid d1-14 q3w
PD-L1 antibodyDrug
1200mg d1 q3w
cetuximab βDrug
250mg/m2 d1, 500mg/m2 d8 q3w
HRS-7058Drug
200mg bid
HRS-4642Drug
500mg d1, 1200mg d8 q3w
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete response (CR) rate: rate of complete response (CR), including the rate of pathologic complete response (pCR) after surgery and the rate of cCR with W&W strategy.Time frame: 1 month after the surgery or 1 year after the decision of W&W.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.